North America Is Expected To Generate 42% of the Global Parenteral Nutrition Market Revenue: Fact.MR Study

Parenteral Nutrition Market

The market for parenteral nutrition accrued significant gains, being valued at over US$ 6 Bn as of 2021. The industry is expected to reach US$ 7 Bn by 2022-end, experiencing Y-o-Y increase of 16% compared to 2021. From 2022-2032, the industry is forecast to increase 2x to reach US$ 14 Bn.

Report Attributes Details
Market Value for 2021 US$ 6 Bn
Anticipated Market Value for 2022 US$ 7 Bn
Forecasted Market Value for 2032 US$ 14 Bn
Global Growth Rate (2022-2032) 7% CAGR
Market Share of North America 42%
Value CAGR of Asia-Pacific 8%

Download Free Sample Copy Of This Report:

Rising Prevalence of Chronic, Non-Communicable Diseases to Augment Growth

Non-communicable diseases (NCDs) lead to 41 million fatalities each year, equivalent to 71% of deaths globally, according to the World Health Organization. Each year, more than 15 million people die from an NCD between the ages of 30 and 69 years, and 85% of these premature deaths occur across low and middle-income countries.

Most of these fatalities arise out of lack of adequate minerals, vitamins or nutrients. Malnutrition is a serious problem plaguing both the developing as well as developed worlds. Currently, nearly 2 billion adults are overweight or obese, while 462 million are underweight.

Increasing Prevalence of Nutritional Deficiency to Augment Adoption

According to Fact.MR, parenteral nutrition revenue is likely to be the largest across North America, expected to gather a market share worth 42% in 2022. Growth is majorly attributed to the increasing prevalence of nutritional inadequacy amongst both adults and children in recent years.

According to Johns Hopkins Medicine, across the United States, a significant proportion of children suffer from malnutrition due to dietary imbalances than due to nutritional deficiencies. About 1% of children across the U.S suffer from chronic malnutrition. Iron deficiency comprises most of the malnutrition cases across the country.

Share Your Requirements & Get Customized Reports:

Competitive Landscape

Prominent parenteral nutrition products manufacturers are striving to continuously improve their product offerings. They do so by introducing new product lines, consolidating their presence through collaborations and acquiring some small to medium-scale providers among others. Some key developments are as follows:

  • In January 2020, Fresenius Kabi completed its clinical trial for SmofKabiven- a new range of lipid emulsions. The product is manufactured from multiple oils, including fish, soybean & olive oils and medium-chain triglycerides.

Key Companies Profiled

  • Allergan Plc.
  • Baxter International
  • Vifor Pharma Group
  • Grifols S.A
  • Otsuka Pharmaceutical Co. Ltd.
  • Fresenius Kabi
  • Braun Melsungen AG
  • Pfizer Inc.
  • Sichuan Kelun Pharmaceutical Co. Ltd.
  • Actavis Inc.

Full Access Of This Report Is Available At:

Key Segments Covered in the Parenteral Nutrition Research Report

  • By Nutrient Type :

    • Carbohydrate-based Parenteral Nutrition Products
    • Parenteral Lipid Emulsion
    • Single Dose Amino Acid Parenteral Nutrition Solution
    • Parenteral Nutrition Trace Elements
    • Parenteral Vitamins & Minerals
Single Dose Amino Acid Parenteral Nutrition Solutions to Remain Prominent

By nutrient type, sales of single dose amino acid parenteral nutrition solutions are expected to remain dominant, with an anticipated market share worth 31% in 2022 and beyond. This is attributed to increased usage of amino acid solutions.

Newly procured amino acids possess fewer side effects, thereby enhancing patient benefits. A combination of different amino acid grades have proven to enhance overall biological functioning of the patient. Hence, there is high reliance on this product.

Prospects for Parenteral Lipid Emulsions are expected to Heighten Significantly

Besides single dose amino acids, lipid emulsions are likely to enjoy rapid growth, expanding at a CAGR of 6.7% from 2022 to 2032. Growth is attributed to development of hybrid parenteral lipid emulsions from multiple sources to enhance patient health.

These formulations are manufactured through a combination of fish oil and olive oil. Moreover, the COVID-19 pandemic has prompted healthcare providers to offer parenteral nutrition over enteral approaches, with lipid emulsions proving to be the most convenient option.

Check Out More Related Studies Published By Fact.MR Research:

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E Mail :